Sun Pharmaceutical Industries Ltd Share Price – NSE  / BSE

Pharmaceuticals, Mid Cap

The American drug regulator had inspected the company?s facility from 8 September 2025 to 19 September 2025. The US FDA has subsequently determined that the inspection classification status of this facility is Official Action Indicated (OAI).

?We continue to manufacture and supply approved products from the facility to the US market. We will work with the regulator to achieve fully compliant status,? the company said in a statement.

Sun Pharmaceutical Industries is the world?s leading specialty generics company with a presence in innovative medicines, generics and consumer healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as global emerging markets.

The company had reported 2.6% rise in consolidated net profit to Rs 3,118 crore on a 8.6% increase in revenue to Rs 14,405.2 crore in Q2 FY26 as compared with Q2 FY25.

Powered by Capital Market - Live News

Sun Pharmaceutical Industries announced that the US FDA conducted an inspection at the Company's Baska facility from 8 September 2025 to 19 September 2025. The US FDA has subsequently determined that the inspection classification status of this facility is Official Action Indicated (OAI).

Powered by Capital Market - Live News

Sun Pharmaceutical Industries announced the launch of its global innovative drug, ILUMYA (Tildrakizumab) in India for moderate-to-severe plaque psoriasis. A novel biologic treatment, ILUMYA has been endorsed widely by dermatologists in the US and worldwide for several years as an effective and safe treatment of moderate to severe plaque psoriasis.

?ILUMYA offers a safe and effective treatment option for patients who are struggling to manage their moderate-to severe plaque psoriasis,? said Kirti Ganorkar, Managing Director, Sun Pharma. ?We are pleased to introduce this novel therapy in India from our global portfolio of innovative medicines. Already available in 35 countries, ILUMYA has consistently demonstrated significant and long-lasting skin clearance, beginning soon after initiation and sustained over years.?

ILUMYA is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials in moderate-to-severe plaque psoriasis. Patients living with moderate-to-severe plaque psoriasis need therapies they can use over long periods of time without loss of efficacy, and data shows that ILUMYA is a sustainable choice for patients over the long term.

Powered by Capital Market - Live News

Sun Pharmaceutical Industries Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 1744.2, up 0.7% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.28% on the day, quoting at 25949.3. The Sensex is at 84711.84, up 0.29%. Sun Pharmaceutical Industries Ltd has risen around 5.43% in last one month.

Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has risen around 3.33% in last one month and is currently quoting at 22593.4, up 0.8% on the day. The volume in the stock stood at 8.35 lakh shares today, compared to the daily average of 17.57 lakh shares in last one month.

The benchmark November futures contract for the stock is quoting at Rs 1748.4, up 0.53% on the day. Sun Pharmaceutical Industries Ltd is down 1.36% in last one year as compared to a 10.27% spurt in NIFTY and a 4.7% spurt in the Nifty Pharma index.

The PE of the stock is 88.9 based on TTM earnings ending September 25.

Powered by Capital Market - Live News